文献速递中医内科中药与中成药合理使用

口服中成药联合西药治疗慢性前列腺炎/慢性盆腔疼痛综合征伴性功能障碍的贝叶斯网络Meta分析

Comparative Efficacy of Oral Chinese Patent Medicine for Chronic Prostatitis/Chronic Pelvic Pain Syndrome With Sexual Dysfunction: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · Front Pharmacol · 2021-05-10

该研究通过贝叶斯网络Meta分析比较不同口服中成药联合西药治疗慢性前列腺炎/慢性盆腔疼痛综合征伴性功能障碍的疗效。共纳入30项RCT、2996例参与者、11种中成药和11种干预措施。结果显示,前列舒通胶囊+西药在改善NIH-CPSI方面最优,苁蓉益肾颗粒+西药在改善IIEF-5方面最优,疏肝益阳胶囊+西药在联合排名中表现最佳,六味地黄丸/右归胶囊+西药在CP/CPPS和SD临床有效率方面均最优。

要点

  • 前列舒通胶囊+西药可能改善NIH-CPSI最优
  • 苁蓉益肾颗粒+西药可能改善IIEF-5最优
  • 六味地黄丸/右归胶囊+西药在临床有效率方面最优

核心结论

  • 前列舒通胶囊、苁蓉益肾颗粒、疏肝益阳胶囊、六味地黄丸/右归胶囊、前列贝喜胶囊联合西药具有成为最优疗法的最大概率。
  • 鉴于研究局限性,上述结果需精心设计的RCT进一步证实。

研究设计与样本

  • 系统检索PubMed、Cochrane Library、Web of Science、Embase、CNKI、VIP和万方数据库,截至2020年11月。
  • 纳入30项RCT,共2996例参与者,涉及11种口服中成药和11种干预措施。
  • 采用Cochrane手册和CONSORT声明评估偏倚风险,使用STATA 13.0和WinBUGS 1.4.3进行统计分析。

主要发现

  • 在NIH-CPSI方面,前列舒通胶囊+西药最可能成为最优治疗。
  • 在IIEF-5方面,苁蓉益肾颗粒+西药最可能成为最优治疗。
  • 在聚类排名图结合NIH-CPSI和IIEF-5方面,疏肝益阳胶囊+西药表现出最高 likelihood 疗效。
  • 六味地黄丸/右归胶囊+西药在CP/CPPS临床有效率和SD临床有效率方面均极可能为最优治疗。

临床怎么用

  • 对于CP/CPPS伴SD患者,可考虑在常规西药基础上联合口服中成药,如前列舒通胶囊、苁蓉益肾颗粒、疏肝益阳胶囊、六味地黄丸/右归胶囊或前列贝喜胶囊。
  • 选择中成药时应结合主要治疗目标:改善前列腺炎症状优先考虑前列舒通胶囊,改善勃起功能优先考虑苁蓉益肾颗粒,提高整体临床有效率优先考虑六味地黄丸/右归胶囊。

局限性

  • 研究存在局限性,结果需精心设计的RCT进一步证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Oral Chinese patent medicine (OCPM) combined with western medicine (WM) are believed to be effective for the therapy of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) with sexual dysfunction (SD). These western medicines mainly involve antibiotics, phosphodiesterase type-5 inhibitor (PDE-5i), α-blockers. But there is no randomized controlled trial (RCT) that directly compares the efficacy of different OCPM. Hence, we operated a network meta-analysis (NMA) to contrast the efficacy of different OCPM for CP/CPPS with SD. Methods: Relevant studies were searched in PubMed, Cochrane Library, Web of Science, Embase, China National Knowledge Infrastructure (CNKI), Chinese Scientific Journal Database (VIP), and Wanfang database. All of the RCTs concentrated on the use of OCPM to cure CP/CPPS with SD from the inception of the databases to November 2020. We appraised the risk of bias under the Cochrane Handbook and CONSORT statement. The data were statistically analyzed via STATA 13.0 and WinBUGS 1.4.3 instrument. Results: Altogether, 30 pieces of literature with 2,996 participants containing 11 oral Chinese patent medicine and 11 interventions were included in the NMA. In terms of The National Institutes of Health chronic prostatitis symptom index (NIH-CPSI), Qianlie Shutong Capsules (QLSTC) + WM had the most possible of being the optimal treatment. In the light of the International Index of Erectile Function (IIEF-5), Congrong Yishen Granules (CRYSG) + WM had the most possible of being the optimal treatment. Shugan Yiyang Capsules (SGYYC) + WM performed the highest likelihood efficacy under cluster rank graph combined NIH-CPSI and IIEF-5. Liuwei Dihuang Pills/Yougui capsules (LWDHP/YGC) + WM had highly possible to be the optimal treatment not only for the clinical effective rate of CP/CPPS but also for the clinical effective rate of SD. Considering four outcomes, QLSTC, CRYSG, SGYYC, LWDHP/YGC, Qianlie Beixi Capsules (QLBXC) plus WM were the best therapy approach for CP/CPPS with SD, especially LWDHP/YGC + WM and QLBXC + WM. Conclusion: Based on the NMA, QLSTC, CRYSG, SGYYC, LWDHP/YGC, QLBXC plus WM demonstrated the maximum probability of being the optimal therapies. Owing to the limitations of this research, these results should be confirmed by elaborate RCTs. Systematic Review Registration: [https://www.crd.york.ac.uk/prospero/], identifier [CRD42021224060].

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Ma H, Nan T, et al. Comparative Efficacy of Oral Chinese Patent Medicine for Chronic Prostatitis/Chronic Pelvic Pain Syndrome With Sexual Dysfunction: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2021. PMID: 34040523. doi:10.3389/fphar.2021.649470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。